The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25
作者：
Serrano, Dolores [1 ]
Torrado, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
Gisbert, Javier P. [2 ]
机构：
[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain
来源：
CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期
关键词：
CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;
D O I：
10.2174/138920012803341393
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
引用
收藏
页码：1303 / 1312
页数：10
相关论文
共 50 条
  • [1] CYP2C19 polymorphism influences Helicobacter pylori eradication
    Kuo, Chao-Hung
    Lu, Chien-Yu
    Shih, Hsiang-Yao
    Liu, Chung-Jung
    Wu, Meng-Chieh
    Hu, Huang-Ming
    Hsu, Wen-Hung
    Yu, Fang-Jung
    Wu, Deng-Chyang
    Kuo, Fu-Chen
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (43) : 16029 - 16036
  • [2] CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection
    Yang, Jyh-Chin
    Lin, Chun-Jung
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (01) : 29 - 41
  • [3] The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole
    Lee, Jeong Hoon
    Jung, Hwoon-Yong
    Choi, Kee Don
    Song, Ho June
    Lee, Gin Hyug
    Kim, Jin-Ho
    GUT AND LIVER, 2010, 4 (02) : 201 - 206
  • [4] Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians
    Chaudhry, A. S.
    Kochhar, R.
    Kohli, K. K.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2009, 130 (04) : 437 - 443
  • [5] Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori
    Furuta, T
    Shirai, N
    Ohashi, K
    Ishizaki, T
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (02): : 131 - 143
  • [6] Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
    Mafuru, Magesa
    Wu, Sanlan
    Mayala, Henry
    Msengwa, Zaituni
    Phillip, Amani
    Mgone, Charles
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1379 - 1389
  • [7] Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication
    Ozdil, Burhan
    Akkiz, Hikmet
    Bayram, Suleyman
    Bekar, Aynur
    Akgollu, Ersin
    Sandikci, Macit
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (01) : 23 - 28
  • [8] CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects
    Sakai, T
    Aoyama, N
    Kita, T
    Sakaeda, T
    Nishiguchi, K
    Nishitora, Y
    Hohda, T
    Sirasaka, D
    Tamura, T
    Tanigawara, Y
    Kasuga, M
    Okumura, K
    PHARMACEUTICAL RESEARCH, 2001, 18 (06) : 721 - 727
  • [9] CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects
    Toshiyuki Sakai
    Nobuo Aoyama
    Tomoko Kita
    Toshiyuki Sakaeda
    Kohshi Nishiguchi
    Yukari Nishitora
    Takashi Hohda
    Daisuke Sirasaka
    Takao Tamura
    Yusuke Tanigawara
    Masato Kasuga
    Katsuhiko Okumura
    Pharmaceutical Research, 2001, 18 : 721 - 727
  • [10] The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis
    Fu, Juan
    Sun, Chang-Feng
    He, Hong-Yan
    Ojha, Suvash Chandra
    Shi, Han
    Deng, Cun-Liang
    Sheng, Yun-Jian
    PHARMACOGENOMICS, 2021, 22 (13) : 859 - 879
12345